A five-year review of chemoradiotherapy practice in anal cancer: Radiotherapy audit results from a cancer centre in Wales, UK.

IF 2 4区医学 Q3 ONCOLOGY Tumori Pub Date : 2024-06-01 Epub Date: 2024-03-29 DOI:10.1177/03008916241241424

Mutahar A Tunio, Nicki Davies, Elliot Caparros, Janis Davies, Stuart Foyle

{"title":"A five-year review of chemoradiotherapy practice in anal cancer: Radiotherapy audit results from a cancer centre in Wales, UK.","authors":"Mutahar A Tunio, Nicki Davies, Elliot Caparros, Janis Davies, Stuart Foyle","doi":"10.1177/03008916241241424","DOIUrl":null,"url":null,"abstract":"Aim: To review a five-year clinical practice of radical chemoradiotherapy (CRT) for anal cancers at a cancer centre in Wales.Methods: A retrospective audit examined the quality of radical CRT for anal cancers treated between November 2016 and November 2021 by investigating seven critical indicators set by Radiation Therapy Oncology Group and ACT II trials, (1) 95% completion of computed tomography simulation within 14 days of consent, (2) 100% CRT delivery within 28 days of computed tomography simulation, (3) 100% CRT delivery within 28 days of consent, (4) overall treatment time of RT 38 days with > 2 days breaks <5%, (5) 75% completion of concurrent chemotherapy, (6) <2% CRT related colostomies, and (7) <2% the 30-days mortality rate.Results: A total of 80 anal cancers received CRT over five years. Around 95.0% underwent computed tomography simulation within 14 days of consent. The observed slight deviation was related to the Covid pandemic in 2020. About 96.3% started CRT within 28 days of computed tomography simulation. The mean duration of CRT was 37.9 days. Radiotherapy (RT) interruptions > 2 days were about 5%, and 67.5% started CRT within 28 days of consent. About 92.5% and 76.2% completed mitomycin and capecitabine without breaks, respectively. The colostomy rate was 1.2%, and the 30-day mortality was 1.2%.Conclusion: Audit results matched with the standards in six domains. Overall treatment time of 37.9 days, colostomy rates of 1.2%, and the 30-day mortality rate of 1.2% were commendable. Overall time interval between consent and CRT delivery can be achieved by time-constrained measures.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"186-192"},"PeriodicalIF":2.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916241241424","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To review a five-year clinical practice of radical chemoradiotherapy (CRT) for anal cancers at a cancer centre in Wales.

Methods: A retrospective audit examined the quality of radical CRT for anal cancers treated between November 2016 and November 2021 by investigating seven critical indicators set by Radiation Therapy Oncology Group and ACT II trials, (1) 95% completion of computed tomography simulation within 14 days of consent, (2) 100% CRT delivery within 28 days of computed tomography simulation, (3) 100% CRT delivery within 28 days of consent, (4) overall treatment time of RT 38 days with > 2 days breaks <5%, (5) 75% completion of concurrent chemotherapy, (6) <2% CRT related colostomies, and (7) <2% the 30-days mortality rate.

Results: A total of 80 anal cancers received CRT over five years. Around 95.0% underwent computed tomography simulation within 14 days of consent. The observed slight deviation was related to the Covid pandemic in 2020. About 96.3% started CRT within 28 days of computed tomography simulation. The mean duration of CRT was 37.9 days. Radiotherapy (RT) interruptions > 2 days were about 5%, and 67.5% started CRT within 28 days of consent. About 92.5% and 76.2% completed mitomycin and capecitabine without breaks, respectively. The colostomy rate was 1.2%, and the 30-day mortality was 1.2%.

Conclusion: Audit results matched with the standards in six domains. Overall treatment time of 37.9 days, colostomy rates of 1.2%, and the 30-day mortality rate of 1.2% were commendable. Overall time interval between consent and CRT delivery can be achieved by time-constrained measures.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肛门癌化放疗五年回顾：英国威尔士一家癌症中心的放疗审计结果。

目的：回顾威尔士一家癌症中心五年来肛门癌根治性化学放疗（CRT）的临床实践：方法：通过回顾性审计检查2016年11月至2021年11月期间肛门癌根治性CRT的治疗质量，调查放射治疗肿瘤学组和ACT II试验设定的七项关键指标：（1）95%的患者在同意后14天内完成计算机断层扫描模拟；（2）100%的患者在同意后28天内完成计算机断层扫描模拟；（3）100%的患者在同意后28天内完成CRT；（4）RT的总体治疗时间为38天，休息时间大于2天结果：五年内共有80例肛门癌患者接受了CRT治疗：五年来，共有 80 例肛门癌接受了 CRT 治疗。约 95.0% 的患者在获得同意后 14 天内接受了计算机断层扫描模拟治疗。观察到的轻微偏差与 2020 年 Covid 大流行有关。约96.3%的患者在计算机断层扫描模拟后28天内开始接受CRT治疗。CRT 的平均持续时间为 37.9 天。放疗（RT）中断时间大于 2 天的患者约占 5%，67.5% 的患者在获得同意后 28 天内开始 CRT。分别约有 92.5% 和 76.2% 的患者在没有中断的情况下完成了丝裂霉素和卡培他滨治疗。结肠造瘘率为1.2%，30天死亡率为1.2%：审计结果在六个方面符合标准。总体治疗时间为 37.9 天，结肠造瘘率为 1.2%，30 天死亡率为 1.2%，值得称赞。从同意到提供 CRT 的总体时间间隔可以通过有时间限制的措施来实现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.